other material
confidence high
sentiment positive
materiality 0.75
Annexon positive real-world evidence study of ANX005 in Guillain-Barré Syndrome shows benefit over IVIg/PE
Annexon, Inc.
- ANX005 30 mg/kg showed faster improvement in muscle strength vs matched IVIg/PE cohort at week 1 (p<0.0001).
- Patients on ANX005 ~2x more likely to be in better health on GBS-Disability Scale at week 8 (p=0.0459).
- Fewer ANX005 patients required mechanical ventilation (15/79 vs 32/79, p=0.022); 12 fewer median days on ventilation and in ICU.
- Planned U.S. Biologics License Application submission for ANX005 in GBS in first half 2025.
- Study used propensity-score matching between Phase 3 patients (n=79) and IGOS global registry patients (n=79).